<DOC>
	<DOCNO>NCT00002033</DOCNO>
	<brief_summary>To compare effect AS-101 placebo clinical efficacy immunologic function HIV positive patient advanced disease . To compare effect AS-101 placebo occurrence disease progression HIV positive patient advanced disease define : ( 1 ) development new diagnostically confirm major opportunistic infection ( ) ; ( 2 ) development AIDS-related dementia . To compare effect zidovudine ( AZT ) plus AS-101 versus AZT alone ( placebo arm ) clinical efficacy immunologic function patient require anti-viral therapy due disease progression . Garlic capsule give study participant mask obvious garlic odor AS-101 .</brief_summary>
	<brief_title>A Third-Party Blinded , Placebo Controlled Comparative Study AS-101 Administered Intravenously HIV Positive Patients With Advanced Disease</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Standard therapy include acyclovir ganciclovir infection develop study period . ( Prophylactic acyclovir permit . ) Standard therapy persistent infection may continue . Immunomodulators specific therapy malignancy ( include Kaposi 's sarcoma ) allow permission WyethAyerst medical monitor . Zidovudine ( AZT ) may add disease progression patient study minimum eight week . Garlic capsule give study participant mask side effect AS101 . Required : Accepted standard prophylaxis patient prior Pneumocystis carinii pneumonia ( PCP ) . Patients must follow : Diagnosis AIDS AIDSrelated complex ( ARC ) . Life expectancy &gt; 6 month . Provide write informed consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Evidence severe liver dysfunction ( serum albumin &lt; 2.5 g/dl , prothrombin time &gt; 15 second SGOT SGPT &gt; 3 x upper limit normal ) , gastrointestinal , renal , respiratory , endocrine , hematologic , cardiovascular system abnormality psychiatric disorder would prevent compliance protocol . Evidence AIDS relate dementia . Presence disseminate Kaposi 's sarcoma define visceral lesion &gt; 20 cutaneous lesion ; Kaposi 's sarcoma without least one AIDS define characteristic . Presence lymphoma . Active opportunistic infection currently require treatment unless infection stabilize continue treatment require prevent relapse ( e.g. , CNS toxoplasmosis resolve tuberculosis ) . Concurrent Medication : Excluded : Prophylactic acyclovir . Immunomodulators specific therapy malignancy ( include Kaposi 's sarcoma ) allow permission WyethAyerst medical monitor . Zidovudine ( AZT ) may add disease progression patient study minimum eight week . Patients follow exclude : Evidence severe organ dysfunction define Exclusion complication specify disease condition . Unlikely unable comply requirement protocol . Prior Medication : Excluded within 8 week study entry : Any immune stimulation agent BCG vaccine , interferon , immune modulators within 8 week . Any immunosuppressive agent within 8 week . Excluded within 12 week study entry : Zidovudine ( AZT ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 1991</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>ammonium trichloro ( dioxoethylene-O , O'- ) tellurute</keyword>
	<keyword>Zidovudine</keyword>
</DOC>